News

GRP named a top economic development organization in the U.S.

RICHMOND, VA – The Greater Richmond Partnership (GRP) was named among the top 20 economic development organizations in the nation according to Site Selection magazine, a national publication targeting site location professionals and corporate executives making relocation decisions.

The 2022 Mac Conway Awards for Excellence in Economic Development, named in honor of Site Selection founding publisher H. McKinley ‘Mac’ Conway, are awarded annually to the top economic development organizations in the country determined by an index of corporate job creation and facility-related capital investment data calculated both cumulatively and per capita. This marks the first time since 2015 the publication has recognized GRP for outstanding work in its field. It was named a top organization four previous years plus two honorable mentions since its inception in 1994.

“In the last two years, we’ve done a lot of work to come out of the pandemic as a stronger and more focused region and organization. This includes benchmarking best of class regions and regional groups,” said Jennifer Wakefield, President and CEO of GRP. “We are thrilled to be recognized among the best economic development organizations in the country yet again. It’s a testament to our strong public-private partnership and the collaboration found throughout the region to bring jobs and investment to Greater Richmond.”

Earlier this year, Site Selection ranked Greater Richmond as the 3rd top metro for economic development projects per capita for 2021.

Read more here.

Recent News

02/01/2023

Engineered BioPharmaceuticals to Expand in Virginia

Governor Glenn Youngkin announced that Engineered BioPharmaceuticals, Inc., a pharmaceutical engineering and manufacturing company dedicated to advancing cost effective, state-of-the-art medicine, will invest $6.1 million to expand in the City of Danville. The company will expand from its current lab space in the Dan River Business Development Center into its first standalone manufacturing facility at

02/01/2023

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced it has entered into an option agreement for the sale of the assets of Purnovate, Inc. (“Purnovate”), a wholly owned subsidiary of Adial, to Adenomed, LLC (“Adenomed”), a new company formed by Purnovate

01/31/2023

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia. Revealed in the peer-reviewed journal Lupus Science and Medicine, the paper details AMPEL’s breakthrough approach to characterize the underlying disease activity from gene expression data obtained from patient blood samples. The FibroGENE® lab